$JYNT

JOINT Corp

1
1
0

No SEC Form 4 filings for $JYNT in the last 30 days.

See all $JYNT insider activity →

JOINT Corp (JYNT): Entry into a Material Definitive Agreement

JOINT Corp (JYNT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On October 1, 2026, we entered into an Asset Purchase Agreement (the “APA”) with The Joint Franchises San Antonio, LLC, a Texas limited liability company, The Joint Franchises DFW, LLC, a Texas limited liability company, The

The Joint Corp. Reports Second Quarter 2026 Financial Results

JOINT Corp (JYNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 The Joint Corp. Reports Second Quarter 2026 Financial Results - Consolidated Net Income Increases $560,000 to $653,000; Adjusted EBITDA From Continuing Operations Increases by $1.4 Million - - Cash Flow from Operating Activities Rises 152% to $2.2 Million, Driving Fr

JYNT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning JYNT (JOINT Corp). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent JYNT coverage spans financial news, mergers & acquisitions and corporate actions.

What's driving JYNT

  • The acquisition consolidates Texas operations, likely improving royalty efficiency and control.

    tradingview.com · Oct 1, 2026

  • The transaction expands JOINT Corp's control over 141 Texas clinics, potentially improving future royalty streams and operational leverage.

    SEC EDGAR 8-K · Oct 1, 2026

  • Results and cash flow improved alongside a capital-light refranchising push, supporting a margin and buyback narrative.

    SEC EDGAR 8-K · Aug 6, 2026

  • Clinic opening supports incremental unit growth narrative for JYNT’s franchise/managed network, but provides no financial guidance or quantified impact.

    prnewswire.com · Jul 1, 2026

  • The director's grant of 5,714 restricted shares indicates confidence in the company's future prospects, potentially signaling positive sentiment among insiders.

    Stock Titan · May 22, 2026

AlphAI scores every news story that mentions JYNT with an AI model for sentiment and relevance, and aggregates insider trades from JOINT Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $JYNT

Score

The Joint Corp. Reports Second Quarter 2026 Financial Results

JOINT Corp (JYNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 The Joint Corp. Reports Second Quarter 2026 Financial Results - Consolidated Net Income Increases $560,000 to $653,000; Adjusted EBITDA From Continuing Operations Increases by $1.4 Million - - Cash Flow from Operating Activities Rises 152% to $2.2 Million, Driving Fr

$JYNTMed

Joint Corp (JYNT) grants 5,714 restricted shares to director DaVella

Joint Corp (JYNT) director Ronald V. DaVella has been granted 5,714 restricted shares of common stock as an equity award, with no purchase price. These shares will fully vest on the earlier of May 20, 2027, or the date of the next annual stockholders' meeting. Following this transaction, DaVella's direct holdings in Joint Corp amount to 23,243 common shares.

Joint Corp. sells 45 California clinics for $2.3 million

The Joint Corp. (NASDAQ:JYNT) has sold 45 corporate-managed chiropractic clinics in Southern California to Elite Chiro Group for approximately $2.3 million, as part of a strategic shift to a capital-light, pure-play franchisor model. This transaction significantly reduces the company's corporate-managed clinics and aligns with "The Joint 2.0" growth strategy. Analysts predict profitability this year and an EPS forecast of $0.29 for fiscal 2026, supported by the company's strong gross profit margin.

$JYNTMed

Joint Corp. price target lowered to $12 from $14 at Roth Capital

Roth Capital lowered its price target for Joint Corp. (JYNT) to $12 from $14, while maintaining a Buy rating. This decision follows Joint Corp.'s Q4 results exceeding estimates and 2026 guidance largely aligning with Roth's model. However, the analyst expressed that management's post-refranchising pro forma model is "underwhelming" despite long-term upside potential.

The Joint Corp. appoints Ron Stilwell as SVP of operations

The Joint Corp. has appointed Ron Stilwell as Senior Vice President of Operations and Patient Experience, effective immediately. Stilwell, bringing three decades of franchise operations experience, will report directly to President and CEO Sanjiv Razdan, aiming to enhance patient experiences and drive growth for the company and its franchisees. This appointment follows a period where the company's stock has been down, despite recent strong earnings and a solid financial health score.

Related tickers